Post-Transplant Lymphoproliferative Disorder Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
DelveInsight has launched a new report on "Post-Transplant Lymphoproliferative Disorder Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Post-Transplant
Lymphoproliferative Disorder Market Insights, Epidemiology, and Market
Forecast-2030" report
delivers an in-depth understanding of the Post-Transplant Lymphoproliferative
Disorder, historical and forecasted epidemiology as well as the Post-Transplant
Lymphoproliferative Disorder market trends in the United States, EU5 (Germany,
Spain, Italy, France, and United Kingdom) and Japan.
·
The overall incidence of PTLD is rather low,
ranging from 1% to 3%.
·
PTLD is one of the most common malignancy,
following nonmelanoma skin cancer.
·
The majority of PTLDs occurs early, within the
first year of HSCT.
·
Literature suggests that approximately 25-50% of
patients respond to a reduction in immunosuppression alone.
- The
Post-Transplant Lymphoproliferative Disorder report covers the descriptive
overview of Post-Transplant Lymphoproliferative Disorder, explaining its
causes, signs and symptoms, pathophysiology, diagnosis and currently
available therapies
- Comprehensive
insight has been provided into the Post-Transplant Lymphoproliferative
Disorder epidemiology and treatment in the 7MM
- Additionally,
an all-inclusive account of both the current and emerging therapies for
Post-Transplant Lymphoproliferative Disorder are provided, along with the
assessment of new therapies, which will have an impact on the current
treatment landscape
- A
detailed review of Post-Transplant Lymphoproliferative Disorder market;
historical and forecasted is included in the report, covering drug
outreach in the 7MM
- The
Post-Transplant Lymphoproliferative Disorder report provides an edge while
developing business strategies, by understanding trends shaping and driving
the global Post-Transplant Lymphoproliferative Disorder market
Request for Free
Sample Report: https://www.delveinsight.com/sample-request/post-transplant-lymphoproliferative-disorder-market
“According to DelveInsight, Post-transplant lymphoproliferative disease affect
males more than females.”
Post-transplant
lymphoproliferative disease (PTLD) is rare, but a well-known
complication of solid organ transplants and hematopoietic stem cell transplantation.
PTLD is related to the Epstein–Barr virus and immunosuppression therapy. It is
a potentially fatal disorder arising after a solid organ transplant (SOT) or
hematopoietic stem cell transplant (HSCT). In adults, PTLD is the second most
common post-SOT malignancy, after non-melanoma skin cancer. PTLD was first
described in the late 1960s in patients following renal transplantation.
Patients with PTLD may have an array of clinical signs and
symptoms, depending on the organ system and the degree of organ involvement.
Some patients can present with clinical emergencies such as intestinal
perforations or fulminant PTLD with disseminated disease mimicking septic
shock. Lymphadenopathy alone is less commonly seen as a presenting sign when
compared to the non-transplant population.
Current diagnosis and classification of PTLD are based on
the 2008 World Health Organization (WHO) system.
Although it is sometimes difficult to clearly distinguish
between these lesions, the WHO divides PTLD into 4 main histologic categories
as Early lesions, Polymorphic PTLD, Monomorphic PTLD, and Classical Hodgkin’s
Lymphoma.
Request for Free
Sample Report: https://www.delveinsight.com/sample-request/post-transplant-lymphoproliferative-disorder-market
- Atara
Biotherapeutics
- Bluebird
bio
- Bristol-Myers
Squibb
- Xencor,
Inc.
- Chiltern
International Inc.
- And
Many Others
- Tab-cel
- And
Many Others
Request for Sample
Pages for More Details: https://www.delveinsight.com/sample-request/post-transplant-lymphoproliferative-disorder-market
1. Key Insights
2. Executive Summary of Post-Transplant
Lymphoproliferative Disorder
3. Competitive Intelligence Analysis for Post-Transplant Lymphoproliferative
Disorder
4. Post-Transplant Lymphoproliferative Disorder: Market
Overview at a Glance
4.1. Post-Transplant Lymphoproliferative Disorder Total
Market Share (%) Distribution in 2017
4.2. Post-Transplant Lymphoproliferative Disorder Total Market
Share (%) Distribution in 2030
5. Post-Transplant Lymphoproliferative Disorder: Disease
Background and Overview
5.1. Introduction
5.2. Post-Transplant Lymphoproliferative
Disorder Sign and Symptoms
5.3. Post-Transplant Lymphoproliferative Disorder Pathophysiology
5.4. Post-Transplant Lymphoproliferative
Disorder Risk Factors
5.5. Post-Transplant Lymphoproliferative
Disorder Diagnosis
6. Patient Journey
7. Post-Transplant Lymphoproliferative Disorder
Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Post-Transplant Lymphoproliferative
Disorder Epidemiology
7.5.1.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Post-Transplant Lymphoproliferative
Disorder Epidemiology
7.5.2.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Post-Transplant Lymphoproliferative
Disorder Epidemiology
7.5.3.1. Post-Transplant Lymphoproliferative
DisorderEpidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Post-Transplant Lymphoproliferative
Disorder Epidemiology
7.5.4.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Post-Transplant
Lymphoproliferative Disorder Epidemiology
7.5.5.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Post-Transplant Lymphoproliferative
Disorder Epidemiology
7.5.6.1. Post-Transplant Lymphoproliferative Disorder
Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical
Practices
8.1. Post-Transplant Lymphoproliferative Disorder Treatment
and Management
8.2. Post-Transplant Lymphoproliferative Disorder Treatment
Algorithm
9. Post-Transplant Lymphoproliferative
Disorder Unmet Needs
10. Key Endpoints of Post-Transplant Lymphoproliferative
Disorder Treatment
11. Post-Transplant Lymphoproliferative Disorder Marketed
Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Post-Transplant Lymphoproliferative
Disorder Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Post-Transplant Lymphoproliferative Disorder: Seven
Major Market Analysis
13.1. Key Findings
13.2. Post-Transplant Lymphoproliferative Disorder Market
Size in 7MM
13.3. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Post-Transplant
Lymphoproliferative Disorder Market Size
15.1.1. Post-Transplant Lymphoproliferative Disorder Total
Market Size in the United States
15.1.2. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Post-Transplant Lymphoproliferative
Disorder Market Size
15.3.1. Post-Transplant Lymphoproliferative Disorder Total
Market Size in Germany
15.3.2. Post-Transplant Lymphoproliferative DisorderMarket
Size by Therapies in Germany
15.4. France Post-Transplant Lymphoproliferative
Disorder Market Size
15.4.1. Post-Transplant Lymphoproliferative Disorder Total
Market Size in France
15.4.2. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in France
15.5. Italy Post-Transplant Lymphoproliferative
Disorder Market Size
15.5.1. Post-Transplant Lymphoproliferative Disorder Total
Market Size in Italy
15.5.2. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in Italy
15.6. Spain Post-Transplant Lymphoproliferative
Disorder Market Size
15.6.1. Post-Transplant Lymphoproliferative Disorder Total
Market Size in Spain
15.6.2. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in Spain
15.7. United Kingdom Post-Transplant
Lymphoproliferative Disorder Market Size
15.7.1. Post-Transplant Lymphoproliferative Disorder Total
Market Size in the United Kingdom
15.7.2. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in the United Kingdom
15.8. Japan Post-Transplant Lymphoproliferative
Disorder Market Outlook
15.8.1. Japan Market Size
15.8.2. Post-Transplant Lymphoproliferative Disorder Total
Market Size in Japan
15.8.3. Post-Transplant Lymphoproliferative Disorder Market
Size by Therapies in Japan
16. Access and Reimbursement Overview of Post-Transplant
Lymphoproliferative Disorder
17. KOL Views
18. Post-Transplant Lymphoproliferative
Disorder Market Drivers
19. Post-Transplant Lymphoproliferative
Disorder Market Barriers
20. Appendix
20.1. Bibliography
20.2. Post-Transplant Lymphoproliferative
Disorder Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/post-transplant-lymphoproliferative-disorder-market
About DelveInsight
DelveInsight is a premier Business Consulting and Market
Research firm focused exclusively on the life science segment. With a wide
array of smart end-to-end solutions, the firm helps the global Pharmaceutical
and Bio-Tech companies formulate prudent business decisions for
Browse through our vast repository from here.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Comments
Post a Comment